{
  "source": "PA-Notification-Velsipity.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 1438-2\nProgram Prior Authorization/Notification\nMedication Velsipity™ (etrasimod)*\n*Velsipity is excluded from coverage for the majority of our benefits\nP&T Approval Date 4/2024, 4/2025\nEffective Date 7/1/2025\n1. Background:\nVelsipity (etrasimod) is a sphingosine 1-phosphate receptor modulator indicated for the\ntreatment of moderately to severely active ulcerative colitis in adults.\n2. Coverage Criteriaa:\nA. Initial Authorization\n1. Velsipity will be approved based on both of the following criteria:\na. Diagnosis of moderately to severely active ulcerative colitis\n-AND-\nb. Patient is not receiving Velsipity in combination with a targeted immunomodulator\n[e.g., adalimumab, Cimzia (certolizumab), Entyvio (vedolizumab), Olumiant\n(baricitinib), Omvoh (mirikizumab-mrkz), Orencia (abatacept), Rinvoq\n(upadacitinib), Simponi (golimumab), Skyrizi (risankizumab), Tremfya\n(guselkumab), ustekinumab, Xeljanz (tofacitinib)]\nAuthorization will be issued for 12 months.\nB. Reauthorization\n1. Velsipity will be approved based on both of the following criteria:\na. Documentation of positive clinical response to Velsipity therapy\n-AND-\nb. Patient is not receiving Velsipity in combination with a targeted immunomodulator\n[e.g., adalimumab, Cimzia (certolizumab), Entyvio (vedolizumab), Olumiant\n(baricitinib), Omvoh (mirikizumab-mrkz), Orencia (abatacept), Rinvoq\n(upadacitinib), Simponi (golimumab), Skyrizi (risankizumab), Tremfya\n(guselkumab), ustekinumab, Xeljanz (tofacitinib)]\nAuthorization will be issued for 12 months.\n© 2025 UnitedHealthcare Services, Inc.\n1\na State mandates may apply. Any federal regulatory requirements and the member specific benefit\nplan coverage may also impact coverage criteria. Other policies and utilization management\nprograms may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous clai",
    "d utilization management\nprograms may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n• Exclusion: Velsipity is excluded from coverage for the majority of our benefits\n• Supply limits and/or Step Therapy may be in place.\n4. References:\n1. Velsipity [package insert]. New York, NY: Pfizer Inc.; June 2024.\nProgram Prior Authorization/Notification – Velsipity (etrasimod)\nChange Control\n4/2024 New program.\n4/2025 Annual review. Updated examples with no change to clinical intent.\nUpdated reference.\n© 2025 UnitedHealthcare Services, Inc.\n2"
  ]
}